MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

PHASE3CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

DRUG

Linagliptin 5mg

Trial Locations (74)

Unknown

Boehringer Ingelheim Investigational Site, Birmingham

Boehringer Ingelheim Investigational Site, Long Beach

Boehringer Ingelheim Investigational Site, North Hollywood

Boehringer Ingelheim Investigational Site, Denver

Boehringer Ingelheim Investigational Site, Miami

Boehringer Ingelheim Investigational Site, Evansville

Boehringer Ingelheim Investigational Site, Flint

Boehringer Ingelheim Investigational Site, Jackson

Boehringer Ingelheim Investigational Site, Asheboro

Boehringer Ingelheim Investigational Site, Charlotte

Boehringer Ingelheim Investigational Site, Fargo

Boehringer Ingelheim Investigational Site, Columbus

Boehringer Ingelheim Investigational Site, Oklahoma City

Boehringer Ingelheim Investigational Site, Knoxville

Boehringer Ingelheim Investigational Site, Houston

Boehringer Ingelheim Investigational Site, Edmonton

Boehringer Ingelheim Investigational Site, Victoria

Boehringer Ingelheim Investigational Site, Mount Pearl

Boehringer Ingelheim Investigational Site, London

Boehringer Ingelheim Investigational Site, Mississauga

Boehringer Ingelheim Investigational Site, Sarnia

Boehringer Ingelheim Investigational Site, Toronto

Boehringer Ingelheim Investigational Site, Waterloo

Boehringer Ingelheim Investigational Site, Gentofte Municipality

Boehringer Ingelheim Investigational Site, Hillerød

Boehringer Ingelheim Investigational Site, Silkeborg

Boehringer Ingelheim Investigational Site, Slagelse

Boehringer Ingelheim Investigational Site, Kerava

Boehringer Ingelheim Investigational Site, Oulu

Boehringer Ingelheim Investigational Site, Tampere

Boehringer Ingelheim Investigational Site, Turku

Boehringer Ingelheim Investigational Site, Bersée

Boehringer Ingelheim Investigational Site, Bourg-des-Comptes

Boehringer Ingelheim Investigational Site, Grenoble

Boehringer Ingelheim Investigational Site, Le Creusot

Boehringer Ingelheim Investigational Site, Marseille

Boehringer Ingelheim Investigational Site, Saint-Mandé

Boehringer Ingelheim Investigational Site, Vénissieux

Boehringer Ingelheim Investigational Site, Vieux-Condé

Boehringer Ingelheim Investigational Site, Aschaffenburg

Boehringer Ingelheim Investigational Site, Aßlar

Boehringer Ingelheim Investigational Site, Dresden

Boehringer Ingelheim Investigational Site, Düsseldorf

Boehringer Ingelheim Investigational Site, Flörsheim

Boehringer Ingelheim Investigational Site, Pirna

Boehringer Ingelheim Investigational Site, Schweinfurt

Boehringer Ingelheim Investigational Site, Aoba-ku,Sendai,Miyagi

Boehringer Ingelheim Investigational Site, Chiyoda-ku,Tokyo

Boehringer Ingelheim Investigational Site, Cyuo-ku,Tokyo

Boehringer Ingelheim Investigational Site, Kita-ku, Osaka, Osaka

Boehringer Ingelheim Investigational Site, Shimizu-ku,Shizuoka city,Shizuoka

Boehringer Ingelheim Investigational Site, Suita,Osaka

Boehringer Ingelheim Investigational Site, Teine-ku,Sapporo,Hokkaido

Boehringer Ingelheim Investigational Site, Cebu City, Philippines

Boehringer Ingelheim Investigational Site, Pasig City, Philippines

Boehringer Ingelheim Investigational Site, San Juan City, Philippines

Boehringer Ingelheim Investigational Site, Goyang

Boehringer Ingelheim Investigational Site, Jinju

Boehringer Ingelheim Investigational Site, Seongnam

Boehringer Ingelheim Investigational Site, Seoul

Boehringer Ingelheim Investigational Site, Wŏnju

Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat

Boehringer Ingelheim Investigational Site, Madrid

Boehringer Ingelheim Investigational Site, Pozuelo de Alarcón

Boehringer Ingelheim Investigational Site, San Sebastián de los Reyes

Boehringer Ingelheim Investigational Site, Valencia

Boehringer Ingelheim Investigational Site, Changhua

Boehringer Ingelheim Investigational Site, Kaohsiung City

Boehringer Ingelheim Investigational Site, New Taipei City

Boehringer Ingelheim Investigational Site, Taichung

Boehringer Ingelheim Investigational Site, Tainan City

Boehringer Ingelheim Investigational Site, Taipei

Boehringer Ingelheim Investigational Site, Hanoi, Vietnam

Boehringer Ingelheim Investigational Site, Ho Chi Minh City

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT01792518 - MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin | Biotech Hunter | Biotech Hunter